Literature DB >> 23692857

Perspectives and future directions for epigenetics in hematology.

Margaret A Goodell1, Lucy A Godley.   

Abstract

Genetic analysis of hematologic malignancies over the past 5 years has revealed abundant mutations in epigenetic regulators in all classes of disorders. Here, we summarize the observations made within our review series on the role of epigenetics in hematology. We highlight the clinical implications of mutations in epigenetic regulators and outline what we envision are some of the major areas that merit future research. Recent findings may have immediate prognostic value, but also offer new targets for drug development. However, the pleiotropic action of these regulators indicates caution is warranted and argues for investment in understanding of their underlying mechanisms of action as we proceed to exploit these findings for the benefit of patients.

Entities:  

Mesh:

Year:  2013        PMID: 23692857      PMCID: PMC3695360          DOI: 10.1182/blood-2013-04-427724

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  68 in total

1.  Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.

Authors:  Yu-Fei He; Bin-Zhong Li; Zheng Li; Peng Liu; Yang Wang; Qingyu Tang; Jianping Ding; Yingying Jia; Zhangcheng Chen; Lin Li; Yan Sun; Xiuxue Li; Qing Dai; Chun-Xiao Song; Kangling Zhang; Chuan He; Guo-Liang Xu
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

2.  DNA methyltransferases control telomere length and telomere recombination in mammalian cells.

Authors:  Susana Gonzalo; Isabel Jaco; Mario F Fraga; Taiping Chen; En Li; Manel Esteller; María A Blasco
Journal:  Nat Cell Biol       Date:  2006-03-26       Impact factor: 28.824

3.  Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors:  Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

Review 7.  The myelodysplastic syndrome as a prototypical epigenetic disease.

Authors:  Jean-Pierre J Issa
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

8.  Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.

Authors:  Matthias Schaefer; Sabine Hagemann; Katharina Hanna; Frank Lyko
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

Review 9.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.

Authors:  Tobias Neff; Scott A Armstrong
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

10.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

View more
  10 in total

1.  EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.

Authors:  Aline Renneville; Peter Van Galen; Matthew C Canver; Marie McConkey; John M Krill-Burger; David M Dorfman; Edward B Holson; Bradley E Bernstein; Stuart H Orkin; Daniel E Bauer; Benjamin L Ebert
Journal:  Blood       Date:  2015-08-28       Impact factor: 22.113

Review 2.  Epigenetics of multiple sclerosis: an updated review.

Authors:  Cem İsmail Küçükali; Murat Kürtüncü; Arzu Çoban; Merve Çebi; Erdem Tüzün
Journal:  Neuromolecular Med       Date:  2014-03-21       Impact factor: 3.843

Review 3.  Origins of aberrant DNA methylation in acute myeloid leukemia.

Authors:  T Schoofs; W E Berdel; C Müller-Tidow
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

4.  Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.

Authors:  Frank G Rücker; Katharina M Lang; Markus Fütterer; Vladimir Komarica; Mathias Schmid; Hartmut Döhner; Richard F Schlenk; Konstanze Döhner; Steen Knudsen; Lars Bullinger
Journal:  Epigenetics       Date:  2016-06-16       Impact factor: 4.528

5.  Long non-coding RNAs control hematopoietic stem cell function.

Authors:  Min Luo; Mira Jeong; Deqiang Sun; Hyun Jung Park; Benjamin A T Rodriguez; Zheng Xia; Liubin Yang; Xiaotian Zhang; Kuanwei Sheng; Gretchen J Darlington; Wei Li; Margaret A Goodell
Journal:  Cell Stem Cell       Date:  2015-03-12       Impact factor: 24.633

6.  The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.

Authors:  Helmut Greim; Debra A Kaden; Richard A Larson; Christine M Palermo; Jerry M Rice; David Ross; Robert Snyder
Journal:  Ann N Y Acad Sci       Date:  2014-02-04       Impact factor: 5.691

Review 7.  Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.

Authors:  Elisabetta Fratta; Barbara Montico; Aurora Rizzo; Francesca Colizzi; Luca Sigalotti; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-08-30

Review 8.  Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.

Authors:  Mark E Issa; Farnaz Sedigheh Takhsha; Wim Vanden Berghe; Muriel Cuendet; Chandra Sekhar Chirumamilla; Claudina Perez-Novo
Journal:  Clin Epigenetics       Date:  2017-02-10       Impact factor: 6.551

Review 9.  Aberrant DNA Methylation of ABC Transporters in Cancer.

Authors:  Katja Zappe; Margit Cichna-Markl
Journal:  Cells       Date:  2020-10-13       Impact factor: 6.600

Review 10.  Cancer epigenetics: Moving forward.

Authors:  Angela Nebbioso; Francesco Paolo Tambaro; Carmela Dell'Aversana; Lucia Altucci
Journal:  PLoS Genet       Date:  2018-06-07       Impact factor: 5.917

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.